The announcement caused a stir at the annual Alzheimer’s Disease Clinical Trials conference held this year in San Francisco. On Tuesday, November 29, the results of a clinical trial in patients with early-stage Alzheimer’s disease treated with a monoclonal antibody called lecanemab were presented to an audience of attentive clinicians. For the first time, a 25% slowing of cognitive decline was observed in participants who received the treatment compared to the placebo group. These data were published on November 29 in the scientific journal NEJM.
Related posts:
This is what happens to your body when you don't get out
The bronchiolitis epidemic still at "a very high level" in metropolitan France
THAT'S WHY kids don't like Brussels sprouts
Tour de France 2022, Preview Stage 20: High-speed time trial with a difficult final
What are Systemic Autoimmune Diseases? Importance of early detection
Reliance Industries Partners with Brookfield and Digital Realty to Launch 'Digital Connection': Indi...
Supersalud affirms that the majority of Colombians transferred from EPS are satisfied
(Highlights) Premier League 2021-22, Week 37, Manchester United v Chelsea